BACKGROUND Transcatheter Aortic Valve Replacement (TAVR) is frequently used to treat patients with symptomatic, severe aortic stenosis in whom surgery is considered to be high-risk or contraindicated. Post-procedural para-valvular leak (PVL) remains a significant issue with a complex etiology. Our objective was to investigate anatomic and procedural predictors of post-TAVR PVL in patients undergoing implantation of the self-expandable Corevalve transcatheter heart valve (THV).
BACKGROUND Transcatheter Aortic Valve Replacement (TAVR) is frequently used to treat patients with symptomatic, severe aortic stenosis in whom surgery is considered to be high-risk or contraindicated. Post-procedural para-valvular leak (PVL) remains a significant issue with a complex etiology. Our objective was to investigate anatomic and procedural predictors of post-TAVR PVL in patients undergoing implantation of the self-expandable Corevalve transcatheter heart valve (THV).
METHODS 82 patients undergoing TAVR with Corevalve THV who underwent pre-procedural multi-detector row computed tomography (MDCT) and intra-procedural transesophageal echocardiography (TEE) were included. PVL severity was graded using modified VARC-2 criteria. Annulus dimensions, annulus angulation from the axial plane, and calcium volume scores1 were measured by MDCT. Preimplant peak transaortic velocity, aortic valve effective orifice area (EOA), left-ventricular stroke volume (LV SV), left-ventricular ejection fraction (LVEF), and post-implant THV dimensions, implant depth, and PVL were assessed by TEE. An independent t-test was used to compare groups.
RESULTS Mean age was 83.0 years and 54% of patients were female. 39 patients (49%) underwent balloon post-dilatation. Age and gender did not significantly differ between patients with > mild and mild PVL. Out of the 82 patients studied, 57 had < mild, 14 had mild, 4 had mild-moderate, and 7 had moderate PVL at the end of the case. No patient had > moderate PVL. Calcium volume score, annulus angle, baseline transaortic peak velocity, and device size were significantly higher in the > mild PVL group (Table 1) . MDCTderived % perimeter oversizing, LVEF, and a novel variable of THV inflow expansion (3-dimensional TEE-derived THV inflow area/ native annulus area) were significantly lower in the > mild PVL group. Native annulus eccentricity, LV SV, baseline aortic valve EOA, and echo-derived implant depth were not significantly different between the 2 groups. University of Leipzig -Heart Centre, Leipzig, Germany; 2 University of Leipzig -Heart Center, Leipzig, Germany BACKGROUND Transfemoral/Trancutaneous aortic valve implantation (TAVI) is an alternative to surgical aortic valve replacement (SAVR) in high risk patients with severe symptomatic aortic stenosis with good hemodynamic and clinical results. But higher rates of significant conduction disturbances with the need for post-interventional pacemaker implantation (PMI) have been reported. Therefore, the aim of analysis was to determine the frequency of conduction disturbances and the need for PMI after TAVI and the impact on procedural and mid-term outcome.
METHODS Patient receiving TAVI at our center between 2006 and 2014 have been enrolled in a prospective single center registry. The occurrence of conduction abnormalities and the need for PMI has been recorded in 1700 consecutive patients treated predominately with the transfemoral approach under local anesthesia. The database was analyzed with regards to significant conduction disturbances, the need for PMI and the impact on survival.
RESULTS Patients with a mean age of 80AE6 years, a mean STS Score of 8.5AE6.2% and a logEuroSCORE of 19.8AE13.6% were treated predominately with the self-expandable Medtronic Core Valve System (MCV, 64%). The balloon-expandable Edwards SAPIEN valves, other devices and valve-in-valve procedures have been performed less frequently (29%, 7%, 4%). The overall pacemaker rate was 28.1% at 30-days and significantly higher in patients treated with the MCV (33.1%) and other valve types (24.3%) as compared with patients treated with the Edwards SAPIEN (17.9%; p<0.036). The predominant conduction disturbances were high grade AV-Block or significant bradycardia in 84% of cases. The length of hospital stay and mortality after 30-days did not differ significantly (14AE7 vs. 13AE8 days, p>0.05; 7.0% vs. 7.3%, p>0.05), whereas patients with a pre-existing PM could be discharged earlier (10AE3days, p<0.05). The one-year mortality of patients with PMI after TAVI was not significantly different either (20.8% vs. 23.3%, p>0.05).
CONCLUSIONS These real-life registry data proof that significant conduction disturbances with the necessity of pacemaker implantation occur frequently. The need of PMI alone does not affect mortality significantly. But further analysis is necessary to evaluate possible side effects of PMI after TAVI. 9 Quebec Heart and Lung Institute, Quebec, Canada; 10 Quebec Heart and Lung Institute, Quebec, Quebec;BACKGROUND Portico valve is a second-generation self-expanding repositionable system with a nitinol stent frame and bovine pericardial leaflets, which is increasingly utilized for transcatheter aortic valve replacement (TAVR) in patients with severe native aortic stenosis at high risk of conventional surgery. In this report, we describe the procedural and early clinical results from an international multicenter registry of Portico implantation in patients with degenerated aortic bioprosthesis (Portico ViV).
METHODS Baseline demographics, procedural and clinical outcomes were collected on standard case report forms and by the Valve-inValve International Data network from 14 centers across three continents. Procedural endpoints included implantation success and coronary obstruction. Clinical endpoints included death, myocardial infarction (MI), stroke, major bleeding at 30 days as defined by Valve Academic Research consortium II (VARCII).
RESULTS 45 patients undergoing Portico ViV were included in analysis. The mean age was 79AE 7 years with STS (mortality) score of 7AE4. These procedures had mainly utilized peripheral arterial access (93%), with transesophageal echocardiogram guidance (60%) for treatment of surgical valve label size 21, >21-<25, and !25mm in 36, 38 and 27% respectively. Four (9%) of the failed surgical bioprostheses were stentless. Successful implantation was achieved in 44 (98%) cases with no malposition events or clinically-evident coronary obstruction. Post implantation valve area was 1.3 AE0.4 cm2, mean gradient of 17.1 AE 7.7 mmHg and ! moderate aortic insufficiency was observed in 3 (7%). One death (2%) related to ischemic stroke occurred within 30 days. Major bleeding and vascular complication in 5 (11%) and 1 (2%) respectively. One patient required permanent pacemaker implantation (2%).
CONCLUSIONS Results from this international multicenter registry show that Portico offers a safe and effective treatment of failed surgical bioprosthesis with an added advantage of device retrievability, resulting in low incidence of malpositioning and coronary obstruction. Additional studies and comparison with other transcatheter devices should further determine the hemodynamic and clinical performance of this device for selection of optimal treatment of high risk patients with failed surgical bioprostheses. BACKGROUND Transcatheter aortic valve implantation (TAVI) is the treatment option of choice for high surgical risk patients presenting with severe symptomatic aortic stenosis. First generation devices were limited by non-negligible TAVI-related complications including !2 paravalvular leak (PVL) and vascular complications that are predictors of mortality. As a result, newer devices have been developed to overcome these limitations. We aimed to compare procedural and clinical outcomes between contemporary and first generation devices. RESULTS 449 patients were included in the 1G, and 179 patients to the 2G. Patients in the FG were older (83.4 vs. 82.1 years, p¼0.03), of a higher risk profile (Euroscore 10 vs. 9.5, p¼0.04) with a similar gender preponderance (female: 61.2% vs. 61.4%, p¼0.79). Peri-procedurally, there was a lower incidence of major or life-threatening bleeding complications in the 2G compared to the 1G (8.4% vs. 21.4%, p<0.001) and !2 PVL (6.1% vs. 17.1%, p¼0.003) with no differences in the rates of stroke (3.3% vs. 1.8%, p¼0.23) or PPM implantation (11.2% vs. 12.7%, p¼0.6) respectively. Mortality at 30-days (3.6% vs. 1.4%, p¼0.77) and at 1-year (11.2% vs. 12.7%, p¼0.81) were similar between groups.
CONCLUSIONS This single-center retrospective study demonstrates that newer generation TAVI devices are associated with a reduction in !2 PVL and major and life-threatening bleeding events when compared to first generation devices. There were no differences in short-term mortality. Longer-term follow-up are required to determine if these short-term procedural improvements are translated into a longer-term outcome benefit. 
